Glioblastoma multiforme has been described as. Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases
|
|
- Justina Norris
- 5 years ago
- Views:
Transcription
1 » This article has been updated from its originally published version to correct units of measure. See the corresponding erratum notice, DOI: / JNS08268a. «J Neurosurg 108: , 109: , 2008 Bevacizumab and irinotecan therapy in glioblastoma multiforme: a series of 13 cases Sheikh A. Ali, M.D., 1 Wassim M. McHayleh, M.D., 2 Asif Ahmad, M.D., 3 Rajesh Sehgal, M.D., 2 Molly Braffet, P.A.-C., 3 Mohsin Rahman, M.D., 3 Ghassan Bejjani, M.D., 4 and David M. Friedland, M.D. 2 1 Department of Medicine, Division of Hematology Oncology, Temple University, Philadelphia; and Departments of 2 Hematology/Oncology, 3 Radiology, and 4 Neurosurgery, University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania Object. Endothelial proliferation has been recognized as a marker of high-grade or aggressive glioma. Bevacizumab is a humanized immunoglobulin G1 monoclonal antibody to vascular endothelial growth factor that has been shown to have activity in malignant gliomas when combined with irinotecan. The authors report on a case series of 13 patients with recurrent heavily pretreated malignant glioma that was treated with the combination of bevacizumab and irinotecan. Methods. Standard therapy with primary resection followed by adjuvant chemotherapy and radiation had failed in all patients. The median number of therapies applied, including initial surgery, was 5 (range 3 7 therapies). Nine patients were started on bevacizumab at a dose of 5 mg/kg every 2 weeks. Four patients received bevacizumab at a dose of 10 mg/kg; irinotecan was given at a dose of 125 mg/kg every week for 3 weeks. Results. Of the 13 treated patients, 10 (77%) had a radiologically demonstrated partial response and 3 (23%) had stable disease. Six patients (46%) had a clinical response. The median time to disease progression while on treatment was 24 weeks. The median overall survival was 27 weeks. The disease progressed in 8 patients, despite an initial response. Five patients are still responding to therapy. Six of the 8 patients whose disease progressed have died. Bevacizumab was discontinued in 2 patients because of nonfatal intracranial bleeding. Conclusions. The combination of bevacizumab and irinotecan is safe and has excellent activity even in this relapsed, heavily pretreated population of patients with high-grade malignant glioma, most of whom would not be candidates for clinical trials. (DOI: /JNS/2008/109/8/0268) Key Words bevacizumab glioblastoma multiforme irinotecan vascular endothelial growth factor Glioblastoma multiforme has been described as an anaplastic, highly cellular tumor with poorly dif ferentiated round or pleomorphic cells, nuclear aty pia, endothelial cell proliferation, neovascularization, and psuedopalisading necrosis. 9 Of the 18,000 primary brain tumors diagnosed annually in the US, more than half are GBMs. 5 They occur most often in the elderly, and they are more common in whites and in males. 5 The median duration of survival in patients with GBMs is 20 weeks with resection, 36 weeks with surgery plus radiation therapy, and weeks with the addition of adjuvant chemotherapy. 12,16 Abbreviations used in this paper: ECOG = Eastern Cooperative Oncology Group; GBM = glioblastoma multiforme. Despite the modest survival benefit provided by adju vant radiation therapy and chemotherapy, the major - ity of pa tients experience a relapse following initial therapy. The prognosis for recurrent malignant gliomas is poor, with a reported median survival < 12 months, median pro gression-free survival < 12 weeks, and response rates < 20%. 15 The optimal treatment for patients with recurrent or progressive GBM is unclear, and there is no widely accepted standard of care. Among the therapeutic options are repeated surgery, repeated radiation therapy, conventional chemotherapy, and experimental treatments. The disappointing results of most therapeutic strategies in the setting of relapse 13,14 have led to efforts to find more effective and better tolerated treatment options, the most promising of which appears to be the combination of the newer agent irinotecan and the angiogenesis inhibitor bevacizumab. 7,11, J. Neurosurg. / Volume 109 / August 2008
2 Bevacizumab and irinotecan therapy in glioblastoma multiforme Endothelial proliferation has been recognized as a marker of high-grade or aggressive glioma in several grading classifications, and it has been demonstrated that the degree of microvascularity as assessed by the endothelial cell/capillary density correlates well with the biological aggressiveness of astrocytic tumors. 1 It has also been demonstrated that malignant glioma cells overexpress nu merous growth factors including vascular endo thelial growth factor 6,10 and epidermal growth factor receptor. 15 Based on this information, angiogenesis inhibition could play a role in the treatment of these highly vascular and aggressive tumors, a hypothesis that has been tested with varying success in both the laboratory 4 and clinical setting. 11 Historically, the results of using chemotherapy for recurrent malignant astrocytomas, particularly GBM, have been mostly disappointing; however, more recent studies have shown that the combination of temozolomide and irinotecan has activity and is of benefit in recurrent malignant gliomas. 8 Even in the past, irinotecan has been reported to have response rates as high as 15% in malignant glioma 3 and is an agent known to have modest activity in this disease, especially when used as combination therapy. It would thus be appropriate to the basic biology of the disease to consider combining an angiogenesis inhibitor such as bevacizumab with a chemotherapeutic agent with demonstrated activity in relapsed GBM such as irinotecan. The first clinical evidence to this effect came from data reported by Stark-Vance, 11 who used the combination of bevacizumab and irinotecan for the treatment of recurrent malignant glioma. In her report Stark- Vance described 1 patient with a complete response, 8 patients with partial responses, and 11 with stable disease among 21 patients treated with a combination of bevacizumab and irinotecan. Her report was bolstered by the results of a Phase II study by Vredenburgh et al., 15 which also showed the activity of this regimen in relapsed pretreated gliomas. These authors reported a response rate of 63% (19 partial responses and 1 complete response) with a median progression-free survival of 23 weeks and an overall 6-month survival probability of 72% in the 32 patients who were enrolled. Recently, Pope et al. 7 described an imaging response rate of 50% in patients treated with the same combination of irinotecan and bevacizumab. In this paper we describe a series of 13 cases in which this novel approach of using a combination of angiogenesis inhibition and chemotherapy was tried with success in a population of heavily pretreated patients with recurrent GBM, including several with marginal (ECOG Grades 2 3) performance status. Methods Patient Population After standard therapy with primary resection followed by adjuvant chemotherapy and radiation had failed, all patients were considered for therapy with bevacizumab and irinotecan. Patients were required to have a histologically proven diagnosis of a high-grade glioma (World Health Organization grade III) and failure of standard J. Neurosurg. / Volume 109 / August 2008 therapy including surgery followed by adjuvant chemotherapy and radiation. They had to be at least 6 weeks out from their most recent brain surgery, and they needed neurosurgical clearance before starting the bevacizumab therapy. Treatment Regimen Nine patients were started on bevacizumab at a dose of 5 mg/kg every 2 weeks and irinotecan at a dose of 125 mg/kg every week for 3 weeks with 1 week off medication. Four patients received bevacizumab at a dose of 10 mg/kg together with irinotecan at mg/kg every 2 weeks. Dose modifications to the irinotecan were made in case of side effects including diarrhea, cytopenias, and poor tolerance. Bevacizumab was to be stopped in case of significant bleeding at any site. Therapy was changed or discontinued if patients had progressive disease as defined by our radiological response criteria. Response Measurement and Criteria Radiographic Response. Radiographic response was measured by comparing each patient s baseline MR imaging performed before the initiation of therapy and serial MR imaging performed every 4 8 weeks after starting therapy. All images were obtained on a GE Signa 1.5-T MR imaging unit. All postcontrast MR images were obtained after the intravenous administration of 20 ml Multihance (gadobenate dimeglumine). Axial T2-weighted fast spin echo, axial T2 FLAIR, axial postcontrast, and coronal postcontrast images were reviewed by a neurora diology staff member (M.R.) and a neuroradiology fellow (A.A.), both of whom were blinded to the clinical outcome. Imaging response criteria were defined as follows: partial response, a > 50% reduction in the overall degree of enhancement, a > 50% reduction in the degree of vasogenic edema, decreased mass effect, and a reduction by at least 25% in maximal tumor diameter; complete response, a complete resolution of vasogenic edema, enhancement, and a nonenhancing tumor; stable disease, a < 50% reduction in the overall degree of enhancement and vasogenic edema, and a < 25% reduction in maximal tumor diameter; and progressive disease, an increase in the degree of enhancement and vasogenic edema by at least 25% and/or an increase in maximal tumor diameter by at least 20%. Clinical Response. Any subjective improvement in neurological function, cognition, speech, mobility, or ability to perform activities of daily living was considered a clinical response. Results Thirteen patients, including 7 men and 6 women, were treated with this regimen (Table 1). The median age was 53 years (range years). All patients had at least 1 recurrence after the initial definitive treatment and before being treated with bevacizumab and irinotecan, for a median number of 5 therapies including the initial surgery (range 3 7 therapies). The median ECOG performance status in our patient population was Grade 2. Of the
3 S. A. Ali et al. TABLE 1 Summary of characteristics in 13 patients with GBM Age at Diagnosis Type of GBM ECOG Performance (yrs), Sex Diagnosed Status Grade 37, F primary 1 76, F primary 1 65, M primary 2 56, F secondary 2 61, F primary 1 62, M secondary 3 40, M primary 1 53, M primary 2 32, F primary 1 46, M primary 1 50, M primary 2 47, M primary 3 57, F primary 2 treated patients, 10 (77%) had a partial response and 3 (23%) had stable disease according to MR imaging (Table 2). Radiographically, the patients showing a response had dramatic reductions in the size of the tumor masses and associated edema (Figs. 1 and 2). Six patients (46%) had a clinical response described as an improvement in neurological deficits or symptoms after starting therapy. The median time to disease progression on treatment was 24 weeks. The median overall survival after treatment had been started was 27 weeks. Of the 13 patients who were treated, 8 have had disease progression despite having an initial response and 5 are still responding to therapy. Six of the 8 patients who demonstrated disease progression have died. Bevacizumab was discontinued in 2 patients because of nonfatal intracranial bleeding. Patients whose disease progressed while on bevacizumab were found to have enhancing tumors. Discussion Approximately 35 years ago, Folkman 2 proposed the hypothesis that solid tumor growth was dependant on the development of tumor-associated blood vessels, a process called angiogenesis. Many studies on experimental and human tumors since then have confirmed the central role played by angiogenesis in various tumors including GBM. 6 Glioblastoma multiforme is a highly malignant and refractory disease that results in a high disease-specific mortality rate. Prior experience has demonstrated long-term survival in only anecdotal cases. Recent reports of authors using therapeutic combinations, including irinotecan and the anti vascular endothelial growth factor monoclonal antibody bevacizumab, have revealed high response rates. In the present series, after using the combination of irinotecan and bevacizumab, we report a partial response rate of 77% together with a progression-free interval of 24 weeks. Many of the patients had symptomatic, palliative benefits from the treatment. What makes these data even more compelling is the fact that this treatment led to substantial responses although the patients had been very TABLE 2 Treatment response and complications in 13 patients with GBM* Radiologically Bevacizu- Time to Dis- Case Initial Clinical Demonstrated mab Dose Survival ease Progres- No. Treatment Resection Response Response Complications (mg/kg) (wks) sion (wks) 1 surgery/xrt, temozolomide complete no PR none surgery/xrt, BCNU wafer, complete no PR intracranial temozolomide bleeding 3 surgery/xrt, temozolomide, complete no PR none BCNU, irinotecan 4 surgery/xrt, temozolomide complete yes stable none vaccine, GKS 5 surgery/xrt, temozolomide complete yes PR none surgery/xrt, temozolomide, incomplete yes PR none carboplatin, etoposide 7 surgery/xrt, temozolomide, complete no PR none CCNU, irinotecan, erlotonib 8 surgery/xrt, temozolomide, complete yes PR DVT thalidomide, etoposide, BCNU wafer, vincristine 9 surgery/xrt, temozolomide, incomplete no stable intracranial BCNU, irinotecan bleeding 10 surgery/xrt, temozolomide, complete no PR none BCNU, paclitaxel 11 surgery/xrt, temozolomide, incomplete no PR none irinotecan, GKS 12 surgery/xrt, temozolomide, incomplete no PR none BCNU, clinical trial 13 surgery/xrt, temozolomide incomplete yes PR none * BCNU = carmustine; CCNU = lomustine; DVT = deep venous thrombosis; GKS = Gamma Knife surgery; PR = partial response; XRT = radiation treatment. No means no response to treatment and no disease progression. Since treatment with bevacizumab and/or irinotecan. 270 J. Neurosurg. / Volume 109 / August 2008
4 Bevacizumab and irinotecan therapy in glioblastoma multiforme Fig. 1. Axial radiographs obtained in a 47-year-old man before (A) and after treatment with irinotecan plus bevacizumab for ~ 19 weeks, showing an initial dramatic reduction in the size of the mass and associated edema (B), followed by progression with an enhancing, more aggressive pattern while on the same treatment (C). heavily pretreated and numerous surgical and medical ther apies had failed before the regimen was started. Additionally, many of these patients had a poor performance status (median ECOG Grade 2), which has historically been associated with a poor outcome 5,8 and would have made them ineligible for clinical trials. These findings sug gest that this angiogenesis-based therapy for GBM is tolerable and consistently active. Although toxicity is gen erally moderate, the antiangiogenesis component of the treatment can produce serious complications, including a risk of intracranial bleeding. When tumor progress - ion occurred, the radiographic features were consistent with the original presentation, showing infiltrative enhanc ing lesions. Although there was no evidence of extra cranial dissemination in anyone in this series, several pa tients had aggressive patterns of disease progression, in cluding gliomatosis cerebri in at least 2 cases. One patient who had undergone salvage surgery after the experimental therapy demonstrated a pathological conversion to glio sarcoma. Conclusions From the limited experience with antiangiogene sis therapy in GBM, it is not yet clear whether disease pro gression during or after this type of therapy will show different clinical or pathological features. Upcoming studies like the current Radiation Therapy Oncol - ogy Group protocol in which investigators will evaluate bevacizumab in combination with irinotecan or temozolomide in GBM at the first recurrence will shed further light on this approach in less heavily pretreated patients and will, we hope, lead to better survival outcomes in this disease. Ultimately, if this regimen proves to be superior Fig. 2. Axial radiographs obtained in a 37-year-old woman before (left) and after (right) treatment with bevacizumab and irinotecan for ~ 8 weeks, showing significant reduction in the mass and mass effect. J. Neurosurg. / Volume 109 / August
5 S. A. Ali et al. to standard therapy, a randomized trial in the immediate perioperative setting will be warranted. References 1. Brem S, Cotran R, Folman J: Tumor angiogenesis: A quantita tive method for histologic grading. J Natl Cancer Inst 48: , Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 285: , Friedman HS, Petros WP, Friedman AH, Schaaf LJ, Kerby T, Lawyer J, et al: Irinotecan therpy in adults with recur rent or progressive malignant glioma. J Clin Oncol 17: , Goldbrunner RH, Bendszus M, Wood J, Kiderlen M, Sasaki M, Tonn JC: PTK787/ZK222584, an inhibitor of vascu lar endothelial growth factor receptor tyrosine kinases, de creas es glioma growth and vascularization. Neurosurgery 55: , Grossman SA, Batara JF: Current management of glioblastoma multiforme. Semin Oncol 31: , Plate KH, Brier KH, Brier G, Weich HA: Vascular endothelial growth factor is a potential tumor angiogenesis factor in human gliomas in vivo. Nature 359: , Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology 66: , Reardon DA, Quinn JA, Rich JN, Desjardins A, Vredenburgh J, Gururangan S, et al: Phase 1 trial of irinotecan plus temozolomide in adults with recurrent malignant glioma. Cancer 104: , Reardon DA, Wen PY: Therapeutic advances in the treat- ment of glioblastoma: rationale and potential role of targeted agents. Oncologist 11: , Shweiki D, Itin A, Soffer D, Keshet E: Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359: , Stark-Vance V: Bevacizumab and CPT-11 in the treatment of relapsed malignant glioma. Neuro-oncol 7:369, Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: , Tatter SB: Recurrent malignant glioma in adults. Curr Treat Options Oncol 3: , Voynov G, Kaufman S, Hong T, Pinkerton A, Simon R, Dowsett R: Treatment of recurrent malignant gliomas with stereotactic intensity modulated radiation therapy. Am J Clin Oncol 25: , Vredenburgh JJ, Desjardins A, Herndon JE, Dowell JM, Reardon DA, Quinn JA, et al: Phase II Trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer Res 13: , Walker MD, Alexander E Jr, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealy J Jr, et al: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49: , 1978 Manuscript submitted May 30, Accepted October 18, Sources of support: none reported. Address correspondence to: Wassim McHayleh, M.D., 5150 Centre Avenue, Pittsburgh, Pennsylvania Mchaylehw@ upmc.edu. 272 J. Neurosurg. / Volume 109 / August 2008
Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma
National Institute for Health and Clinical Excellence Health Technology Appraisal Carmustine implants and Temozolomide for the treatment of newly diagnosed high grade glioma Personal statement Conventional
More informationIt s s Always Something!
It s s Always Something! New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D. When Something Is a Brain Tumor Brain tumors aren t rare: there are over 100,000/yr Most originate as other cancers
More informationNational Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008
Bevacizumab (Avastin) for glioblastoma multiforme - relapsed August 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationCitation Pediatrics international (2015), 57.
Title Long-term efficacy of bevacizumab a pediatric glioblastoma. Umeda, Katsutsugu; Shibata, Hirofum Author(s) Hiramatsu, Hidefumi; Arakawa, Yoshi Nishiuchi, Ritsuo; Adachi, Souichi; Ken-Ichiro Citation
More informationBevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma
Original Article Bevacizumab rescue therapy extends the survival in patients with recurrent malignant glioma Lin-Bo Cai, Juan Li, Ming-Yao Lai, Chang-Guo Shan, Zong-De Lian, Wei-Ping Hong, Jun-Jie Zhen,
More informationTreatment With Bevacizumab and Irinotecan for Recurrent High-Grade Glial Tumors
2267 Treatment With Bevacizumab and Irinotecan for Recurrent High-Grade Glial Tumors Felix Bokstein, MD 1 Shulim Shpigel, MD 2 Deborah T. Blumenthal, MD 1 1 Neuro-Oncology Service, Tel Aviv Sourasky Medical
More informationCNS Tumors: The Med Onc Perspective. Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U.
CNS Tumors: The Med Onc Perspective Ronald J. Scheff, MD Associate Clinical Professor Weill Medical College of Cornell U. Disclosure Speakers Bureau, Merck Basic Oncology Concepts Tissue Diagnosis Stage
More information21/03/2017. Disclosure. Practice Changing Articles in Neuro Oncology for 2016/17. Gliomas. Objectives. Gliomas. No conflicts to declare
Practice Changing Articles in Neuro Oncology for 2016/17 Disclosure No conflicts to declare Frances Cusano, BScPharm, ACPR April 21, 2017 Objectives Gliomas To describe the patient selection, methodology
More informationA Single Institution s Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma
REVIEW A Single Institution s Experience with Bevacizumab in Combination with Cytotoxic Chemotherapy in Progressive Malignant Glioma Tina Mayer, Jill Lacy and Joachim Baehring Medical Oncology, Yale University
More informationClinical Management Protocol Chemotherapy [Glioblastoma Multiforme (CNS)] Protocol for Planning and Treatment
Protocol for Planning and Treatment The process to be followed when a course of chemotherapy is required to treat: GLIOBLASTOMA MULTIFORME (CNS) Patient information given at each stage following agreed
More informationGlioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D)
Glioblastoma: Adjuvant Treatment Abdulrazag Ajlan, MD, MSc, FRCSC, UCNS(D) *Neurosurgery Consultant, King Saud University, Riyadh, KSA *Adjunct Teaching Faculty, Neurosurgery, Stanford School Of Medicine,
More informationContemporary Management of Glioblastoma
Contemporary Management of Glioblastoma Incidence Rates of Primary Brain Tumors Central Brain Tumor Registry of the United States, 1992-1997 100 Number of Cases per 100,000 Population 10 1 0.1 x I x I
More informationNew Approaches in Brain Tumor Treatment. Virginia Stark-Vance, M.D.
New Approaches in Brain Tumor Treatment Virginia Stark-Vance, M.D. The Primary Brain Tumors es for PicturesMCD for 004.JPG 00 Meningioma 30% Glioblastoma 20% Astrocytoma 10% Nerve sheath 8% Pituitary 6%
More informationBevacizumab: A Controversial Agent Against High-Grade Gliomas
Tumor Bevacizumab: A Controversial Agent Against High-Grade Gliomas Sussan Salas, MD 1, Miguel Guzman, MD 2, Kevin Judy, MD 1 1 Department of Neurological Surgery, Thomas Jefferson University, Philadelphia,
More informationBevacizumab for Recurrent Glioblastoma Multiforme: A Meta-Analysis
403 Multiforme: A Meta-Analysis Eric T. Wong, MD a ; Shiva Gautam, PhD b ; Christopher Malchow a ; Melody Lun c ; Edward Pan, MD d ; and Steven Brem, MD d ; Boston, Massachusetts, and Tampa, Florida Key
More informationNewcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment
Newcastle Neuro-oncology Team Audit of Outcome of Glioblastoma Multiforme Chemoradiotherapy Treatment Jennifer Wright Neurosurgery SSC Audit Team Jennifer Wright, Rachel Tresman, Cyril Dubois, Surash Surash,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES CENTRAL NERVOUS SYSTEM ANAPLASTIC GLIOMAS CNS Site Group Anaplastic Gliomas Author: Dr. Norm Laperriere Date: February 20, 2018 1. INTRODUCTION
More informationTreatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma: A case series.
School of Medicine Digital Commons@Becker Open Access Publications 2016 Treatment with Tumor-Treating Fields therapy and pulse dose bevacizumab in patients with bevacizumab-refractory recurrent glioblastoma:
More informationAntibody-Drug Conjugates in Glioblastoma Multiforme: Finding Ways Forward
Transcript Details This is a transcript of a continuing medical education (CME) activity accessible on the ReachMD network. Additional media formats for the activity and full activity details (including
More informationScottish Medicines Consortium
Scottish Medicines Consortium temozolomide 5, 20, 100 and 250mg capsules (Temodal ) Schering Plough UK Ltd No. (244/06) New indication: for the treatment of newly diagnosed glioblastoma multiforme concomitantly
More informationCPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2 neu-positive breast cancer
CPT-11/bevacizumab for the treatment of refractory brain metastases in patients with HER2 neu-positive breast cancer The Harvard community has made this article openly available. Please share how this
More informationBrain Tumors: Radiologic Perspective
Brain Tumors: Radiologic Perspective Alberto Bizzi, M.D. Neuroradiology Humanitas Research Hospital Milan, Italy The job of the neuroradiologist in the work-up of brain tumors has quite changed in the
More informationBC Cancer Protocol Summary for Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine
BC Cancer Protocol Summary for Palliative Therapy for Recurrent Malignant Gliomas Using Bevacizumab With or Without Concurrent Etoposide or Lomustine Protocol Code Tumour Group Contact Physician CNBEV
More informationJ Clin Oncol 25: by American Society of Clinical Oncology INTRODUCTION
VOLUME 25 NUMBER 30 OCTOBER 20 2007 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Bevacizumab Plus Irinotecan in Recurrent Glioblastoma Multiforme James J. Vredenburgh, Annick Desjardins, James
More informationBevacizumab and dose-intense temozolomide in recurrent high-grade glioma
Annals of Oncology 21: 1723 1727, 2010 doi:10.1093/annonc/mdp591 Published online 11 January 2010 Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma J. J. C. Verhoeff 1, C. Lavini
More informationPROCARBAZINE, lomustine, and vincristine (PCV) is
RAPID PUBLICATION Procarbazine, Lomustine, and Vincristine () Chemotherapy for Anaplastic Astrocytoma: A Retrospective Review of Radiation Therapy Oncology Group Protocols Comparing Survival With Carmustine
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org The Role of Radiosurgery in the Treatment of Gliomas Luis Souhami, MD Professor Department of Radiation
More informationClinical Trials for Adult Brain Tumors - the Imaging Perspective
Clinical Trials for Adult Brain Tumors - the Imaging Perspective Whitney B. Pope, M.D., Ph.D. Department of Radiology David Geffen School of Medicine at UCLA August 22, 2015 1 Disclosure of Financial Relationships
More informationGoing Past the Data for Temozolomide. J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D.
Going Past the Data for Temozolomide J. Lee Villano, M.D., Ph.D., Nathalie Letarte, B.Pharm, M.Sc, Linda R. Bressler, Pharm. D. Departments of Medicine (JLV), Neurosurgery (JLV) and Pharmacy Practice (LRB)
More informationMalignant gliomas are the most common type of primary. Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas
PRACTICE OF ONCOLOGY: RECENT ADVANCES Bevacizumab and Irinotecan in the Treatment of Recurrent Malignant Gliomas John F. de Groot, MD, and Wai Kwan Alfred Yung, MD Abstract: Rapidly dividing glioma cells
More informationAppraisal of carmustine. implants and temozolomide. for newly diagnosed high. Brain and Spine Foundation
Appraisal of carmustine implants and temozolomide for newly diagnosed high grade glioma Brain and Spine Foundation June 2005 Submission to the National Institute for Health and Clinical Excellence Brain
More informationGlioblastoma: Current Treatment Approach 8/20/2018
Glioblastoma: Current Treatment Approach 8/20/2018 Overview What is Glioblastoma? How is it diagnosed How is it treated? Principles of Treatment Surgery, Radiation, Chemotherapy Current Standard of care
More informationUniversity of Zurich. Temozolomide and MGMT forever? Zurich Open Repository and Archive. Weller, M. Year: 2010
University of Zurich Zurich Open Repository and Archive Winterthurerstr. 190 CH-8057 Zurich Year: 2010 Temozolomide and MGMT forever? Weller, M Weller, M (2010). Temozolomide and MGMT forever? Neuro-Oncology,
More informationSystemic Treatment. Third International Neuro-Oncology Course. 23 May 2014
Low-Grade Astrocytoma of the CNS: Systemic Treatment Third International Neuro-Oncology Course São Paulo, Brazil 23 May 2014 John de Groot, MD Associate Professor, Neuro-Oncology UT MD Anderson Cancer
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationNational Institute for Health and Clinical Excellence. Single Technology Appraisal (STA)
National Institute for Health and Clinical Excellence Appendix C Comment 1: the draft scope Single Technology Appraisal (STA) Carmustine implants for the treatment of recurrent glioblastoma multiforme
More informationProtocol Abstract and Schema
Protocol Abstract and Schema Phase II study of Bevacizumab plus Irinotecan (Camptosar ) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas,
More informationPRESURGICAL PLANNING. Strongly consider neuropsychological evaluation before functional imaging study Strongly consider functional imaging study
NOTE: Consider Clinical Trials as treatment options for eligible patients. Page 1 of 6 RADIOLOGICAL PRESENTATION PRESURGICAL PLANNING TREATMENT Imaging study suggestive of glioma 1 Left hemisphere speech/motor
More informationJ Clin Oncol 27: by American Society of Clinical Oncology INTRODUCTION
VOLUME 27 NUMBER 28 OCTOBER 1 29 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T From the Brain Tumor Center, Duke University, Durham, NC; Department of Neurosurgery, University of California,
More informationEfficacy and safety of bevacizumab and etoposide combination in patients with recurrent malignant gliomas who have failed bevacizumab
Reviews in Health Care 2014; 5(1): 23-32 Drugs Narrative review Efficacy and safety of bevacizumab and etoposide combination in patients with recurrent malignant gliomas who have failed bevacizumab Jose
More informationUPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS
UPDATES ON CHEMOTHERAPY FOR LOW GRADE GLIOMAS Antonio M. Omuro Department of Neurology Memorial Sloan-Kettering Cancer Center II International Neuro-Oncology Congress Sao Paulo, 08/17/12 CHALLENGES IN
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 20, 2018 Avastin Description Avastin
More informationCorporate Medical Policy
Corporate Medical Policy Analysis of MGMT Promoter Methylation in Malignant Gliomas File Name: Origination: Last CAP Review: Next CAP Review: Last Review: analysis_of_mgmt_promoter_methylation_in_malignant_gliomas
More informationPOLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS BENEFIT VARIATIONS DISCLAIMER CODING INFORMATION REFERENCES POLICY HISTORY
Original Issue Date (Created): November 26, 2013 Most Recent Review Date (Revised): November 26, 2013 Effective Date: April 1, 2014 POLICY PRODUCT VARIATIONS DESCRIPTION/BACKGROUND RATIONALE DEFINITIONS
More informationRecurrent Glioblastoma Multiforme: Implication of Nonenhancing Lesions on Bevacizumab Treatment
J Interdiscipl Histopathol 2013; 1(4): 217-222 ISSN: 2146-8362 Case Report Recurrent Glioblastoma Multiforme: Implication of Nonenhancing Lesions on Bevacizumab Treatment Daniela Alexandru 1, Hung-Wen
More information1. Introduction. Correspondence should be addressed to Christopher M. Lee; Received 9 July 2013; Accepted 27 August 2013
Case Reports in Oncological Medicine Volume 2013, Article ID 431857, 5 pages http://dx.doi.org/10.1155/2013/431857 Case Report Long-Term Survival and Improved Quality of Life following Multiple Repeat
More informationConcomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study
Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: A retrospective study T Sridhar 1, A Gore 1, I Boiangiu 1, D Machin 2, R P Symonds 3 1. Department of Oncology, Leicester
More informationIncidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide
405 Incidence of Early Pseudo-progression in a Cohort of Malignant Glioma Patients Treated With Chemoirradiation With Temozolomide Walter Taal, MD 1 Dieta Brandsma, MD, PhD 1 Hein G. de Bruin, MD, PhD
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationAvastin (bevacizumab) DRUG.00028, CG-DRUG-68
Avastin (bevacizumab) DRUG.00028, CG-DRUG-68 Override(s) Prior Authorization Approval Duration 1 year Medications Avastin (bevacizumab) APPROVAL CRITERIA Requests for Avastin (bevacizumab) may be approved
More informationTemozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience
Temozolomide with Radiotherapy for the Treatment of Malignant Gliomas, Center Experience *Ehab Abdou and **Mohamed Gaafar *Department of Radiation Oncology, Faculty of Medicine, Al-Azhar University, Cairo,
More informationMALIGNANT GLIOMAS: TREATMENT AND CHALLENGES
MALIGNANT GLIOMAS: TREATMENT AND CHALLENGES DISCLOSURE No conflicts of interest to disclose Patricia Bruns APRN, CNS Givens Brain Tumor Center Abbott Northwestern Hospital October 12, 2018 OBJECTIVES THEN
More informationRebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma
DOI 10.1007/s11060-010-0121-0 CLINICAL STUDY - PATIENT STUDY Rebound tumour progression after the cessation of bevacizumab therapy in patients with recurrent high-grade glioma Richard M. Zuniga Roy Torcuator
More information3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors
research article 213 3-D conformal radiotherapy with concomitant and adjuvant temozolomide for patients with glioblastoma multiforme and evaluation of prognostic factors Yilmaz Tezcan and Mehmet Koc Department
More informationTumor-Treatment Fields Therapy for Glioblastoma
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationDouglas Jolly Executive VP R&D Tocagen Inc.
REPLICATING RETROVIRUSES FOR MANIPULATION OF THE TUMOR IMMUNE ECOSYSTEM: PRECLINICAL AND CLINICAL OUTCOMES. Douglas Jolly Executive VP R&D Tocagen Inc. PEGS 2018 IT Track Boston May 1 2018 Outline Phase
More informationCURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION *
CURRENT CONTROVERSIES IN THE MANAGEMENT OF HIGH GRADE GLIOMAS: AN INTERACTIVE CASE DISCUSSION * Alessandro Olivi, MD, Jaishri Blakeley, MD, and Allen K. Sills, MD, FACS ABSTRACT The management of glioma
More informationLung Cancer in Women: A Different Disease? James J. Stark, MD, FACP
Lung Cancer in Women: A Different Disease? James J. Stark, MD, FACP Medical Director, Cancer Program and Director of Palliative Care Maryview Medical Center Professor of Medicine Eastern Virginia Medical
More informationNeuro-Oncology Advance Access published April 4, 2012
Neuro-Oncology Advance Access published April 4, 2012 Neuro-Oncology doi:10.1093/neuonc/nos070 NEURO-ONCOLOGY Response assessment in recurrent glioblastoma treated with irinotecan-bevacizumab: comparative
More informationDescription. Section: Durable Medical Equipment Effective Date: January 15, 2016 Subsection: Original Policy Date: December 6, 2013 Subject:
Last Review Status/Date: December 2015 Page: 1 of 9 Description multiforme is the most common and deadly malignant brain tumor. It has a very poor prognosis and is associated with low quality of life during
More informationInnovative Multimodal Imaging Techniques in Brain Tumor Clinical Trials
Innovative Multimodal Imaging Techniques in Brain Tumor Clinical Trials Benjamin M. Ellingson, Ph.D. Assistant Professor of Radiology, Biomedical Physics, and Bioengineering Brain Tumor Imaging Laboratory
More information성균관대학교삼성창원병원신경외과학교실신경종양학 김영준. KNS-MT-03 (April 15, 2015)
성균관대학교삼성창원병원신경외과학교실신경종양학 김영준 INTRODUCTIONS Low grade gliomas (LGG) - heterogeneous group of tumors with astrocytic, oligodendroglial, ependymal, or mixed cellular histology - In adults diffuse, infiltrating
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.04.04 Subject: Avastin Page: 1 of 8 Last Review Date: December 3, 2015 Avastin Description Avastin (bevacizumab)
More informationJohn D. Hainsworth, MD, Kent C. Shih, MD, Gregg C. Shepard, MD, Guy W. Tillinghast, MD, Brett T. Brinker, MD, and David R. Spigel, MD.
Phase II Study of Concurrent Radiation Therapy, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus as First- Line Treatment for Patients With Glioblastoma John D. Hainsworth, MD, Kent C.
More informationTemozolomide in the treatment of recurrent malignant glioma in Chinese patients!"#$%&'()*+,-./0,1234
Key words: Astrocytoma; Brain neoplasms; Disease-free survival; Glioblastoma; Neoplasm recurrence!!"!"!"#$ DTM Chan WS Poon YL Chan HK Ng Hong Kong Med J 2005;11:452-6 The Chinese University of Hong Kong,
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor_treatment_fields_therapy 9/2013 11/2017 11/2018 6/2018 Description of Procedure or Service Tumor-treatment
More informationHypofractionated radiation therapy for glioblastoma
Hypofractionated radiation therapy for glioblastoma Luis Souhami, MD, FASTRO Professor McGill University Department of Oncology, Division of Radiation Oncology Montreal Canada McGill University Health
More informationManagement of Glioma: The Basics Glioma Update The clinical challenge. Glioma a malignant disease of the CNS
Management of Glioma: The Basics Glioma Update 3 oger Stupp, MD Department of Oncology & Cancer Center University Hospital Zurich, Switzerland (roger.stupp@usz.ch) Bern, 3. August 3 The clinical challenge
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: September 15, 2017 Avastin Description Avastin
More informationIntegrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach?
Perspective Page 1 of 5 Integrating bevacizumab and radiation treatment of brain metastasis: is there sense and sensibility in this approach? Emil Lou 1, Paul W. Sperduto 2 1 Division of Hematology, Oncology
More informationClinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: PA.CP.MP.145
Clinical Policy: Electric Tumor Treating Fields (Optune) Reference Number: PA.CP.MP.145 Effective Date: 01/18 Last Review Date: 04/18 Coding Implications Revision Log Description Electric tumor treating
More informationEnormous effort has been invested in clinical trials for malignant
Published February 13, 2008 as 10.3174/ajnr.A0963 REVIEW ARTICLE J.W. Henson S. Ulmer G.J. Harris Brain Tumor Imaging in Clinical Trials SUMMARY: There are substantial challenges in the radiologic evaluation
More informationAvastin. Avastin (bevacizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.04 Subject: Avastin Page: 1 of 9 Last Review Date: June 22, 2017 Avastin Description Avastin (bevacizumab)
More informationUNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
More informationPrecision medicine for gliomas
Precision medicine for YAZMIN ODIA, MD MS LEAD PHYSICIAN OF MEDICAL NEURO-ONCOLOGY DISCLOSURES Novocure: Advisory Board for Optune in No other financial conflicts of interest Glioma OVERVIEW INFILTRATIVE,
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationBC Cancer Protocol Summary for Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent and Adjuvant Temozolomide and Radiation Therapy
BC Cancer Protocol Summary for Treatment of Elderly Newly Diagnosed Glioma Patient with Concurrent Adjuvant Temozolomide Radiation Therapy Protocol Code Tumour Group Contact Physician CNELTZRT Neuro-Oncology
More informationLOW GRADE ASTROCYTOMAS
LOW GRADE ASTROCYTOMAS This article was provided to us by David Schiff, MD, Associate Professor of Neurology, Neurosurgery, and Medicine at University of Virginia, Charlottesville. We appreciate his generous
More informationMolecular Imaging in the Development of Cancer Therapeutics. Johannes Czernin
Molecular Imaging in the Development of Cancer Therapeutics Johannes Czernin Ahmanson Biological Imaging Division University of California Los Angeles Cancer Statistics Cancer Type 5-year Survival Rate
More informationCNS SESSION 3/8/ th Multidisciplinary Management of Cancers: A Case based Approach
CNS SESSION Chair: Ruben Fragoso, MD/PhD UC Davis Fellow: Michael Cardenas, MD UC Davis Panel: Gordon Li, MD Stanford Seema Nagpal, MD Stanford Jennie Taylor, MD UCSF HPI: 46 yo right handed woman who
More informationImaging for suspected glioma
Imaging for suspected glioma 1.1.1 Offer standard structural MRI (defined as T2 weighted, FLAIR, DWI series and T1 pre- and post-contrast volume) as the initial diagnostic test for suspected glioma, unless
More informationAssessment of treatment response in high grade gliomas: RANO criteria usage for an accurate radiology report.
Assessment of treatment response in high grade gliomas: RANO criteria usage for an accurate radiology report. Poster No.: C-2167 Congress: ECR 2014 Type: Educational Exhibit Authors: F. Facal de Castro,
More informationBrain Tumors. Andrew J. Fabiano, MD FAANS. Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine
Brain Tumors Andrew J. Fabiano, MD FAANS Associate Professor of Neurosurgery Roswell Park Cancer Institute SUNY at Buffalo School of Medicine Brain Tumors Brain Tumor Basics Types of Tumors Cases Brain
More informationTargeted Therapies in Metastatic Colorectal Cancer: An Update
Targeted Therapies in Metastatic Colorectal Cancer: An Update ASCO 2007: Targeted Therapies in Metastatic Colorectal Cancer: An Update Bevacizumab is effective in combination with XELOX or FOLFOX-4 Bevacizumab
More informationAvastin (bevacizumab)
Avastin (bevacizumab) Policy Number: 5.02.502 Last Review: 04/2018 Origination: 03/2017 Next Review: 04/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Avastin
More informationMedical Necessity Guideline
(MNG) Title: Electric Tumor Treatment Field Therapy MNG #: 003 SCO One Care Prior Authorization Needed? Yes No Clinical: Operational: Informational: Medicare Benefit: Yes No Last Revised Date: 1/25/2019;
More informationPediatric Brain Tumors: Updates in Treatment and Care
Pediatric Brain Tumors: Updates in Treatment and Care Writer Classroom Rishi R. Lulla, MD MS Objectives Introduce the common pediatric brain tumors Discuss current treatment strategies for pediatric brain
More informationCorporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma
Corporate Medical Policy Tumor-Treatment Fields Therapy for Glioblastoma File Name: Origination: Last CAP Review: Next CAP Review: Last Review: tumor-treatment_fields_therapy_for_glioblastoma 9/2013 11/2017
More informationCritical Clinical Updates
Critical Clinical Updates ASTRO Spring Refresher Course JW Marriott Hotel Ramesh Rengan MD PhD Department of Radiation Oncology Friday March 22, 2013 Learning Objectives At the conclusion of this activity,
More informationAntiangiogenic drugs in unresectable glioblastoma. Dra. Carmen Balañá. /
Antiangiogenic drugs in unresectable glioblastoma Dra. Carmen Balañá. / Outcome for unresectable GBM Overall survival for unresectable GBM without further treatment is: 3 months at most. Radiotherapy increases
More informationDurable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment
Durable Responses Observed in Recurrent High Grade Glioma (rhgg) with Toca 511 & Toca FC Treatment Cloughesy TF 1, Landolfi J 2, Vogelbaum MA 3, Ostertag D 4, Elder JB 5, Bloomfield S 2, Carter B 6, Chen
More informationRINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA
RINDOPEPIMUT (CDX-110) IN GLIOBLASTOMA MULTIFORM GEINO 2014 Dra Estela Pineda Madrid Hospital Clínic Barcelona EGFRvIII in glioblastoma multiform The most common mutation of EGFR in GBM Expressed in 30%
More informationAccepted 24 October 2007 Published online 22 January 2008 in Wiley InterScience (www.interscience.wiley.com). DOI: /hed.
ORIGINAL ARTICLE PHASE II STUDY OF GEFITINIB FOR THE TREATMENT OF RECURRENT AND METASTATIC NASOPHARYNGEAL CARCINOMA Daniel T. T. Chua, MD, 1 William I. Wei, MD, 2 Maria P. Wong, MD, 3 Jonathan S. T. Sham,
More informationRetrospective Study of The Corticosteroids Administration in Glioblastoma Patients as A Prognostic Factor in The Disease
The Egyptian Journal of Hospital Medicine (July 2018) Vol. 72 (5), Page 4551-4555 Retrospective Study of The Corticosteroids Administration in Glioblastoma Patients as A Prognostic Factor in The Disease
More informationORIGINAL PAPERS. The Impact of Surgery on the Efficacy of Adjuvant Therapy in Glioblastoma Multiforme
ORIGINAL PAPERS Adv Clin Exp Med 2015, 24, 2, 279 287 DOI: 10.17219/acem/40456 Copyright by Wroclaw Medical University ISSN 1899 5276 Anna Brzozowska 1, 2, A D, Anna Toruń 3, G, Maria Mazurkiewicz1, 2,
More informationSurvival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy: A Retrospective Comparative Study
Original Article Research in Oncology June 2017; Vol. 13, No. 1: 18-22. DOI: 10.21608/resoncol.2017.552.1022 Survival of High Grade Glioma Patients Treated by Three Radiation Schedules with Chemotherapy:
More informationTitle: Carmustine (BCNU) for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors
Author's response to reviews Title: Carmustine (BCNU) for recurrent glioblastoma multiforme: efficacy, toxicity and prognostic factors Authors: Thomas P Reithmeier (thomas.reithmeier@uniklinik-freiburg.de)
More informationTHE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION. Mustafa Rashid Issa
THE EFFECTIVE OF BRAIN CANCER AND XAY BETWEEN THEORY AND IMPLEMENTATION Mustafa Rashid Issa ABSTRACT: Illustrate malignant tumors that form either in the brain or in the nerves originating in the brain.
More informationAssessing Response of High-Grade Gliomas to Immune Checkpoint Inhibitors
linicians may encounter unique challenges when evaluating the imaging response of GMs treated with immunotherapy and checkpoint inhibitors. Irena Orlov. Industrial feel 21. igital on canvas, 40" 60". ssessing
More informationProcarbazine Lomustine and VinCRIStine (PCV) Therapy INDICATIONS FOR USE:
Procarbazine Lomustine and VinCRIStine (PCV) Therapy INDICATIONS FOR USE: INDICATION ICD10 Protocol Code Adjuvant treatment of Grade II glioma administered after C71 00379a radiotherapy Palliative treatment
More information